http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110452298-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_da2f79017444789d747982d4ab13b908 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-24 |
| filingDate | 2019-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3b0cbad2a43173e8e98458f8fe0dd23 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17b4165f4c49778675851343ae673cba http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4a91cff1aa317ea0ff13bf644719727 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3e4735d200dacc79daaa3957fc090c3 |
| publicationDate | 2019-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110452298-A |
| titleOfInvention | A liver-targeting ligand and its application in liposome preparations |
| abstract | The invention discloses a liver-targeting ligand and its application in liposome preparations. The ligand is a single-chain antibody fragment obtained by hydrolyzing hepatocyte growth factor with pancreatic elastase, including an N-terminal hairpin structure and The four Kringle structures are the NK4 liver targeting ligands; the NK4 liver targeting is the NK4 protein molecule. The present invention also utilizes the principle of specific binding of the ligand NK4 to the hepatocyte growth factor c-Met receptor, and uses the HGF single-chain antibody fragment NK4 as the liver-targeting ligand to prepare NK4 surface-modified liposome preparations to mediate active drug targeting. Targeting the liver tissue; it can not only achieve the purpose of targeted recognition and binding to liver cancer cells, but also block the activity of the HGF/c-Met signaling pathway through NK4, inhibit the growth of tumor cells, and synergistically enhance the anti-tumor effect of the drug. NK4-mediated liposome drug delivery system has great application potential in the targeted therapy of liver tumors. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111557910-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111557910-A |
| priorityDate | 2019-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 101.